KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Preferred Shares (2018 - 2021)

Xenon Pharmaceuticals (XENE) has disclosed Preferred Shares for 6 consecutive years, with $7.7 million as the latest value for Q4 2021.

  • Quarterly Preferred Shares changed 0.0% to $7.7 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $7.7 million through Dec 2021, changed 0.0% year-over-year, with the annual reading at $7.7 million for FY2021, 0.0% changed from the prior year.
  • Preferred Shares for Q4 2021 was $7.7 million at Xenon Pharmaceuticals, roughly flat from $7.7 million in the prior quarter.
  • The five-year high for Preferred Shares was $21.8 million in Q1 2018, with the low at $7.7 million in Q1 2019.
  • Average Preferred Shares over 4 years is $9.9 million, with a median of $7.7 million recorded in 2019.
  • The sharpest move saw Preferred Shares crashed 64.57% in 2019, then changed 0.0% in 2020.
  • Over 4 years, Preferred Shares stood at $11.9 million in 2018, then crashed by 35.2% to $7.7 million in 2019, then changed by 0.0% to $7.7 million in 2020, then changed by 0.0% to $7.7 million in 2021.
  • According to Business Quant data, Preferred Shares over the past three periods came in at $7.7 million, $7.7 million, and $7.7 million for Q4 2021, Q3 2021, and Q2 2021 respectively.